MedTrace Logo

A Study of Cisapride in Premature Infants With Feeding Problems

NCT01281566 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2011-01-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness of Cisapride in improving feeding problems in premature newborn infants.

Conditions

  • Infant, Premature
  • Infant, Newborn

Interventions

DRUG

Placebo

liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days

DRUG

Cisapride

0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days

Sponsors & Collaborators

  • Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
36 Weeks
Max Age
99 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Completion
2003-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01281566 on ClinicalTrials.gov